Breast cancer risk associated with CHEK2 mutations

Area of Science:

• Oncology
• Genetics
• Cancer Research

Background:

• Historically, hereditary breast cancer risk assessment primarily focused on BRCA1 and BRCA2 gene mutations.
• Less common susceptibility genes, including CHEK2, also confer increased breast cancer risk but were often overlooked.
• Advances in next-generation sequencing (NGS) enable comprehensive genetic testing for multiple cancer risk genes.

Purpose of the Study:

• To highlight the growing importance of the CHEK2 gene in hereditary breast cancer.
• To inform oncology nurses about CHEK2 mutations and their clinical implications.
• To emphasize the role of NGS in identifying a broader spectrum of hereditary cancer risks.

Main Methods:

• Review of current literature on hereditary breast cancer genetics.
• Analysis of the inclusion of CHEK2 in next-generation sequencing panels.
• Discussion of clinical management strategies for CHEK2 mutation carriers.

Main Results:

• CHEK2 is increasingly identified as a significant hereditary breast cancer susceptibility gene.
• NGS panels commonly incorporate CHEK2 testing, leading to more frequent detection of mutations.
• Oncology nurses require updated knowledge to address CHEK2-related hereditary cancer risks.

Conclusions:

• The scope of hereditary breast cancer gene testing has expanded beyond BRCA1/BRCA2.
• CHEK2 mutations represent a notable risk factor requiring clinical attention.
• Educating healthcare professionals, particularly oncology nurses, is vital for effective patient care regarding CHEK2.